Qiu Chen, Feng Dai
Department of Pharmacy, Hongshan District Health Service Center, Wuhan 430000, Hubei Province, China.
Department of Ear-Nose-Throat, Wuchang Hospital Affiliated to Wuhan University of Science and Technology, Wuhan 430063, Hubei Province, China.
World J Clin Cases. 2023 Oct 6;11(28):6725-6732. doi: 10.12998/wjcc.v11.i28.6725.
There are many adverse reactions in the treatment of allergic rhinitis (AR) mainly with conventional drugs. Leukotriene receptor antagonists, glucocorticoids and nasal antihistamines can all be used as first-line drugs for AR, but the clinical effects of the three drugs are not clear.
To examine the impact of glucocorticoids, antihistamines, and leukotriene receptor antagonists on individuals diagnosed with AR, specifically focusing on their influence on serum inflammatory indexes.
The present retrospective study focused on the clinical data of 80 patients diagnosed and treated for AR at our hospital between May 2019 and May 2021. The participants were categorized into the control group and the observation group. The control group received leukotriene receptor antagonists, while the observation group was administered glucocorticoids and antihistamines. Conducted an observation and comparison of the symptoms, physical sign scores, adverse reactions, and effects on serum inflammatory indexes in two distinct groups of patients, both before and after treatment.
Subsequent to treatment, the nasal itching score, sneeze score, runny nose score, nasal congestion score, and physical signs score exhibited notable discrepancies ( < 0.05), with the observation group demonstrating superior outcomes compared to the control group ( < 0.05). The interleukin (IL)-6, IL-10, tumor necrosis factor-alpha, Soluble Intercellular Adhesion Molecule-1, Leukotriene D4 after treatment were significantly different and the observation group It is better than the control group, which is statistically significant ( < 0.05). Following the intervention, the incidence of adverse reactions in the observation group, including symptoms such as nasal dryness, discomfort in the throat, bitter taste in the mouth, and minor erosion of the nasal mucosa, was found to be 7.5%. This rate was significantly lower compared to the control group, which reported an incidence of 27.5%. The difference between the two groups was statistically significant ( < 0.05).
Glucocorticoids and antihistamines have obvious therapeutic effects, reduce serum inflammatory index levels, relieve symptoms and signs of patients, and promote patients' recovery, which can provide a reference for clinical treatment of AR.
过敏性鼻炎(AR)的治疗主要采用传统药物,存在诸多不良反应。白三烯受体拮抗剂、糖皮质激素和鼻用抗组胺药均可作为AR的一线用药,但这三种药物的临床效果尚不明确。
研究糖皮质激素、抗组胺药和白三烯受体拮抗剂对AR患者的影响,重点关注其对血清炎症指标的影响。
本回顾性研究聚焦于2019年5月至2021年5月期间在我院诊断并治疗的80例AR患者的临床资料。将参与者分为对照组和观察组。对照组接受白三烯受体拮抗剂治疗,观察组给予糖皮质激素和抗组胺药治疗。对两组患者治疗前后的症状、体征评分、不良反应以及对血清炎症指标的影响进行观察和比较。
治疗后,鼻痒评分、喷嚏评分、流涕评分、鼻塞评分及体征评分差异显著(P<0.05),观察组疗效优于对照组(P<0.05)。治疗后白细胞介素(IL)-6、IL-10、肿瘤坏死因子-α、可溶性细胞间黏附分子-1、白三烯D4差异有统计学意义,观察组优于对照组(P<0.05)。干预后,观察组出现鼻干、咽喉不适、口苦、鼻黏膜轻度糜烂等不良反应的发生率为7.5%,明显低于对照组的27.5%,两组差异有统计学意义(P<0.05)。
糖皮质激素和抗组胺药具有明显的治疗效果,可降低血清炎症指标水平,缓解患者症状和体征,促进患者康复,可为AR的临床治疗提供参考。